Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Don't want ads? Click here
Sponsored Content
Don't want ads? Click here

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.10
Bid: 9.00
Ask: 9.20
Change: 0.00 (0.00%)
Spread: 0.20 (2.222%)
Open: 8.85
High: 9.10
Low: 8.85
Prev. Close: 9.00
ANIC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Timelines are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

All G Co Update

27 Nov 2024 07:00

RNS Number : 7649N
Agronomics Limited
27 November 2024
 

 

Agronomics Limited

27 November 2024

 Agronomics Ltd

("Agronomics" or the "Company")

All G Receives Approval for Sale of Recombinant Bovine Lactoferrin in China

Agronomics (LSE: ANIC), a leading listed company in the field of cellular agriculture, is delighted to announce that its portfolio company, All G Co Holdings Pty Limited ("All G"), is the first company in the world to receive regulatory clearance for the sale of recombinant bovine lactoferrin in China.

All G is an Australian-based biotechnology company at the forefront of using precision fermentation to develop high-value, animal-free proteins for use in a variety of markets - ranging from functional foods, medical nutrition and infant nutrition. 

Lactoferrin, a whey protein found in human and cow milk, is highly sought-after for its numerous functional benefits, including enhancing gut function, iron absorption and providing antimicrobial and anti-inflammatory benefits. However, due to its low concentration in cow's milk, it is expensive to produce and yields only limited quantities, creating a major opportunity for alternative protein producers.

China represents one of the largest consumers of lactoferrin globally, driven by a growing demand for functional foods and health-conscious consumers. The approval allows for the sale of All G's product into a specific target market which will be disclosed closer to the time of market entry. The company is simultaneously progressing with regulatory approval for the use of its lactoferrin in infant formula, which is expected in 2025.

This approval is significant for All G, as it will allow the company to bring in initial revenue streams in advance of its Series B fund raise. Revenues are projected to be at positive margins as All G aims to produce at or below price parity compared with conventionally produced lactoferrin. All G intends to release its first lactoferrin product in 2025 and plans to receive approval for its products in the US, Australia, New Zealand, and Japan.

All G's regulatory approval in China comes after only three years of operations. To date, All G has raised AU$ 45 million and was named Food & Beverage Startup of the Year by the Food and Beverage Accelerator in Australia for its work in changing dairy protein production. Agronomics has invested AU$ 15 million into All G since inception, which is currently carried at £7.9 million as of 30 June 2024.

Commenting on the announcement, Jan Pacas, All G CEO, said: "This approval is a great moment for All G as we lead the way in precision fermentation technology. Lactoferrin is one of the most valuable and functional proteins in the world. Our technology unlocks its potential, and this is just the beginning - our recombinant human lactoferrin is progressing rapidly, with many other products in the pipeline."

Jim Mellon, Agronomics' Executive Chair, added: "Today's announcement is another testament to the strength of the Agronomics portfolio. All G is one of the leading technology companies developing animal-free proteins and achieving regulatory approval for Lactoferrin in China - the world's largest market - is an exciting step for the industry. More importantly, it provides a platform from which All G can bring other key products to market at competitive prices."

About All G

All G is a Sydney-based biotechnology company that is at the forefront of precision fermentation, developing high-value, animal-free proteins for use in functional foods, medical nutrition and infant nutrition. Founded in 2020 by CEO Jan Pacas, the company has successfully raised AU$ 45 million and is planning to launch its first lactoferrin product in 2025.

About Agronomics

Agronomics is a leading London-listed company focussing on investment opportunities within the field of cellular agriculture. The Company has established a portfolio of over 20 companies in this rapidly advancing sector. It seeks to invest in companies owning technologies with defensible intellectual property that offer new ways of producing food and materials with a focus on products historically derived from animals. These technologies are driving a major disruption in agriculture, offering solutions to improve sustainability, as well as addressing human health, animal welfare and environmental damage. This disruption will decouple supply chains from the environment and animals and improve food security for the world's expanding population. A full list of Agronomics' portfolio companies is available at https://agronomics.im/.

For further information please contact:

Agronomics Limited

Beaumont Cornish Limited

Canaccord Genuity Limited

Cavendish Securities Plc

Peterhouse Capital Limited

SEC Newgate

The Company

Nomad

Joint Broker

Joint Broker

Joint Broker

Public Relations

Jim Mellon

Denham Eke

Roland Cornish

James Biddle

Andrew Potts

Harry Pardoe

Alex Aylen (Head of Equities)

Giles Balleny

Michael Johnson

Lucy Williams

Charles Goodfellow

Bob Huxford

Anthony Hughes

+44 (0) 1624 639396

info@agronomics.im

+44 (0) 207 628 3396

+44 (0) 207 523 8000

+44 (0) 207 397 8900

+44 (0) 207 469 0936

agronomics@secnewgate.co.uk

 

Nominated Adviser

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFEMEFMELSESF
Date   Source Headline
18th Jul 202511:00 amRNSNet Asset Value calculation as at 30 June 2025
11th Jun 20257:00 amRNS-RAgronomics Q2 2025 Newsletter
28th May 20252:55 pmRNS-RMeatly reduces bioreactor and medium costs
12th May 20257:00 amRNSNet Asset Value calculation as at 31 March 2025
8th May 20257:00 amRNS-RLiberation Labs Announce Manufacturing Partnership
6th May 20257:00 amRNS-RMeatable and TruMeat Forge Alliance
30th Apr 20257:00 amRNS-RBlueNalu Expands Partnership with Nomad Foods
15th Apr 20259:00 amRNS-RLiberation Labs secures strategic partnership
18th Mar 20257:00 amRNSExercise of Shellbay options
14th Mar 20258:15 amRNSUnaudited Interim Results
4th Mar 20258:00 amRNS-RSolar Foods Secures €10 million Grant
7th Feb 20253:33 pmRNSResult of AGM
7th Feb 20257:00 amRNS-RMeatly launches first cultivated meat dog treat
4th Feb 20254:20 pmRNSDirector/PDMR Shareholding
4th Feb 20257:00 amRNSNet Asset Value calculation as at 31 December 2024
30th Jan 20257:00 amRNSLiberation Labs Closes US$ 50.5 million Fundraise
21st Jan 20254:33 pmRNSFormo Secures a €35 million loan
24th Dec 202412:37 pmRNSFinal Results and Notice of AGM
13th Dec 20243:55 pmRNSExercise of Warrants, Total Voting Rights
28th Nov 20247:00 amRNSNet Asset Value calculation at 30 September 2024
27th Nov 20247:00 amRNS-RAll G Co Update
15th Oct 20244:36 pmRNSAgronomics invests US$ 2m in Liberation Labs
15th Oct 20247:00 amRNSAgronomics invests US$2m in Liberation Labs
10th Oct 20244:20 pmRNSJim Mellon – Director’s Dealing and PDMR
8th Oct 202411:30 amRNSJim Mellon – Director’s Dealing and PDMR
7th Oct 202411:52 amRNSExercise of Warrants & TVR
4th Oct 20241:57 pmRNSHolding(s) in Company
27th Sep 20247:00 amRNSShellbay Appoints New Chief Executive Officer
24th Sep 20249:00 amRNSMeatable awarded €7.6 million Innovation Credit
10th Sep 20247:00 amRNSFormo Closes a US$ 61 Million Series B Round
4th Sep 20247:00 amRNSGALY Raises US$ 33 Million in Series B Financing
8th Aug 20245:13 pmRNSHolding(s) in Company
8th Aug 20247:00 amRNSNAV Statement, Warrant Exercise, TVR
18th Jul 20247:00 amRNSOnego Bio Secures EUR 14 million in New Funding
17th Jul 20248:00 amRNSMeatly Receives Clearance for Cultivated Pet Food
6th Jun 20247:00 amRNSExercise of Warrants & TVR
29th May 20247:00 amRNSPortfolio Company Presentation – Clean Food Group
23rd May 20241:01 pmRNSMeatable Appoints Jeff Tripician as New CEO
7th May 20247:00 amRNSNet Asset Value calculation as at 31 March 2024
7th May 20247:00 amRNSMeatly Unveils Protein-Free Medium
26th Apr 20247:00 amRNSSolar Foods Raises an Additional EUR8 Million
22nd Apr 20247:00 amRNSAgronomics Newsletter
17th Apr 20247:00 amRNSMosa Meat Raises EUR 40 Million in New Financing
12th Apr 20247:00 amRNSExercise of Warrants
10th Apr 20249:30 amRNSPortfolio Company Presentation Series – Onego Bio
5th Apr 20247:00 amRNSAgronomics Invests US$10m in Liberation Labs
2nd Apr 20247:00 amRNSOnego Bio Raises EUR37 Million
26th Mar 20247:09 amRNSClean Food secures £2.5m additional funding
21st Mar 20245:40 pmRNSSuperMeat Update
20th Mar 202410:37 amRNSFormo Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.